ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
2,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
3,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
3,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,3,Fungal skin infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
4,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
4,2,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
5,1,Conjunctivitis allergic,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
5,2,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
6,1,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
6,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
7,1,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
8,1,Device leakage,Device issues NEC,Device issues,Prod,N
8,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
8,3,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
9,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
10,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
10,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
11,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
11,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
12,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
12,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
13,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
14,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
14,2,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
14,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
14,4,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
15,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
16,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
17,1,Headache,Headaches NEC,Headaches,Nerv,N
18,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
19,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
20,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
21,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
21,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
21,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
22,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
23,1,Headache,Headaches NEC,Headaches,Nerv,N
23,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,3,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
24,1,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
25,1,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
26,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
27,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
28,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
29,1,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
30,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
30,2,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
30,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
31,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
31,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
31,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
32,1,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
32,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
33,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
34,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
34,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
35,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
36,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
37,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
37,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
37,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
37,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
37,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
37,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
38,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
39,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
39,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
40,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
41,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
42,1,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
42,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
42,3,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
43,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
44,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
44,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
44,3,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
44,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
44,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
45,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
45,2,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
45,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
45,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
45,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
45,6,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
46,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
46,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
46,3,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
46,4,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
46,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
46,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
46,7,Scratch,Skin injuries NEC,Injuries NEC,Inj&P,N
46,8,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
47,2,Headache,Headaches NEC,Headaches,Nerv,N
47,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
47,4,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
47,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
48,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
49,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
50,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
50,2,Exposure via skin contact,Pathways and sources of exposure,"Exposures, chemical injuries and poisoning",Inj&P,N
50,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
50,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
51,1,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
51,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
51,3,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
51,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
52,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
52,2,Injection site indentation,Injection site reactions,Administration site reactions,Genrl,N
53,1,Injection site indentation,Injection site reactions,Administration site reactions,Genrl,N
54,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
55,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
56,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
56,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
57,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
57,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
57,3,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
58,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
59,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
59,2,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
60,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
61,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
62,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
63,1,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
64,1,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
65,1,Device issue,Device issues NEC,Device issues,Prod,N
65,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
